About This Trial

Anti-amyloid antibody targeting N3pG amyloid for earlier-stage Alzheimer's patients.

Primary Endpoints

  • iADRS score change
  • Amyloid plaque clearance

Latest Update

February 2026

FDA approved Kisunla (donanemab) in July 2025. Post-marketing study confirms 35% slowing of decline at 18 months.

Lead Investigators

DR
Dr. Reisa SperlingDirector, Center for Alzheimer Research, BWH